A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments
Latest Information Update: 18 Dec 2023
Price :
$35 *
At a glance
- Drugs Fremanezumab (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms FOCUS
- Sponsors Teva Branded Pharmaceutical Products R&D
- 06 Dec 2023 According to a Teva Pharmaceuticals media release, data from this study were presented at the 2023 European Headache Congress.
- 06 Dec 2023 Post hoc results presented in a Teva Pharmaceuticals media release.
- 13 Nov 2023 Results of post hoc analysis assessing determine the number needed to treat (NNT), number needed to harm (NNH), and likelihood of being helped or harmed published in the Headache